Literature DB >> 24999188

MicroRNA-145 directly targets the insulin-like growth factor receptor I in human bladder cancer cells.

Zhaowei Zhu1, Tianyuan Xu1, Li Wang2, Xianjin Wang1, Shan Zhong1, Chen Xu2, Zhoujun Shen3.   

Abstract

The insulin-like growth factor receptor I (IGF-IR) is a proto-oncogene with potent mitogenic and antiapoptotic activities. It has been reported that expression of IGF-IR is up-regulated in bladder cancer. Here, we assessed whether microRNA-145 (miR-145) regulates IGF-IR expression in bladder cancer. In our study, miR-145 was shown to directly target IGF-IR 3'-untranslated region (UTR) in human bladder cancer cells. Small interfering RNA (siRNA)- and miR-145-mediated IGF-IR knockdown experiments revealed that miR-145 promotes cell apoptosis, and suppresses cell proliferation and migration through suppression of IGF-IR expression. Taken together, our data suggest that miR-145 may inhibit bladder cancer initiation by affecting IGF-IR signaling.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; Bladder cancer; IGF-IR; Migration; Proliferation; miR-145

Mesh:

Substances:

Year:  2014        PMID: 24999188     DOI: 10.1016/j.febslet.2014.06.059

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  23 in total

Review 1.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

2.  Cisplatin and Paclitaxel Alter the Expression Pattern of miR-143/145 and miR-183/96/182 Clusters in T24 Bladder Cancer Cells.

Authors:  Emmanuel I Papadopoulos; Andreas Scorilas
Journal:  Clin Transl Sci       Date:  2015-09-10       Impact factor: 4.689

3.  miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling.

Authors:  Hengbing Wang; Qi Li; Xiaobing Niu; Gongcheng Wang; Sinian Zheng; Guangbo Fu; Zengjun Wang
Journal:  Oncol Lett       Date:  2016-11-16       Impact factor: 2.967

4.  CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis.

Authors:  Ozel Capik; Fatma Sanli; Ali Kurt; Onur Ceylan; Ilknur Suer; Murat Kaya; Michael Ittmann; Omer Faruk Karatas
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-03-22       Impact factor: 5.554

5.  Regulation of microRNA during cardiomyocyte maturation in sheep.

Authors:  Janna L Morrison; Song Zhang; Ross L Tellam; Doug A Brooks; I Caroline McMillen; Enzo R Porrello; Kimberley J Botting
Journal:  BMC Genomics       Date:  2015-07-22       Impact factor: 3.969

6.  A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer.

Authors:  Hui Zhou; Kun Tang; Haibing Xiao; Jin Zeng; Wei Guan; Xiaolin Guo; Hua Xu; Zhangqun Ye
Journal:  J Exp Clin Cancer Res       Date:  2015-05-21

7.  MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer.

Authors:  Jiaojiao Su; Hongwei Liang; Weiyan Yao; Nan Wang; Suyang Zhang; Xin Yan; Hui Feng; Wenjing Pang; Yanbo Wang; Xueliang Wang; Zhen Fu; Yanqing Liu; Chihao Zhao; Junfeng Zhang; Chen-Yu Zhang; Ke Zen; Xi Chen; Yalei Wang
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

8.  MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.

Authors:  Sheema Khan; Mara C Ebeling; Mohd S Zaman; Mohammed Sikander; Murali M Yallapu; Neeraj Chauhan; Ashley M Yacoubian; Stephen W Behrman; Nadeem Zafar; Deepak Kumar; Paul A Thompson; Meena Jaggi; Subhash C Chauhan
Journal:  Oncotarget       Date:  2014-09-15

Review 9.  Regulation of IGF -1 signaling by microRNAs.

Authors:  Hwa Jin Jung; Yousin Suh
Journal:  Front Genet       Date:  2015-01-13       Impact factor: 4.599

10.  A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer.

Authors:  Jun Wu; Qun Huang; Dongdong Meng; Minyu Huang; Chaowen Li; Tianzi Qin
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.